In a patent (US Pat. No. 10,660,865) issued this week assigned to Mor Research Applications and STERO Biotechs, CBD is described as being capable of preventing and treating Graft-Versus-Host Disease (GVHD). When someone receives a tissue transplant, if the tissue contains immune cells, they may attack the host's tissues, known as a graft-vs-host reaction.
Patent ‘865 teaches a method of preventing and treating a patient with GVHD that will undergo an allogeneic hematopoietic stem cell transplant - a transplant from a related donor or from someone with a similar genetic makeup. A drug containing CBD, cyclosporine, and immunosuppressive drugs is administered to the patient 14 days before the transplant process and either 1 to 30 days or 7 to 180 days after the procedure.
Mor Research Applications is the Technology Transfer Office of Clalit Health Services and is based in Tel Aviv, IL and was created in partnership with STERO Biotechs, a clinical stage company focused on R&D of novel CBD therapies, also based in Israel. Explore cannabis-based pharmaceuticals and compositions using Magic Number’s Cannabis Patent Forecast®.
